BMS-816336

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H27NO3
Molecular Weight	341.444
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BMS-816336

Structure Search

SMILES

OC1CN(C1)C(=O)CC2(C3CC4CC2CC(C3)C4O)C5=CC=CC=C5

InChI

InChIKey=OAAZMUGLOXGVNH-UHFFFAOYSA-N

InChI=1S/C21H27NO3/c23-18-11-22(12-18)19(24)10-21(15-4-2-1-3-5-15)16-6-13-7-17(21)9-14(8-16)20(13)25/h1-5,13-14,16-18,20,23,25H,6-12H2

HIDE SMILES / InChI

Molecular Formula	C21H27NO3
Molecular Weight	341.444
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:44:24 GMT 2023` Edited by `admin` on `Sat Dec 16 11:44:24 GMT 2023`
Record UNII	HLF8J24L87
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-816336

Common Name

English

ETHANONE, 1-(3-HYDROXY-1-AZETIDINYL)-2-(6-HYDROXY-2-PHENYLTRICYCLO(3.3.1.13,7)DEC-2-YL)-

Systematic Name

English

1-(3-HYDROXYAZETIDIN-1-YL)-2-(6-HYDROXY-2-PHENYL-2-ADAMANTYL)ETHANONE

Systematic Name

English

Code System Code Type Description

FDA UNII

HLF8J24L87

Created by admin on Sat Dec 16 11:44:24 GMT 2023 , Edited by admin on Sat Dec 16 11:44:24 GMT 2023

PRIMARY

CLINICAL_TRIALS.GOV

BMS-816336

Created by admin on Sat Dec 16 11:44:24 GMT 2023 , Edited by admin on Sat Dec 16 11:44:24 GMT 2023

PRIMARY

Official Title: Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects;Purpose: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.

CAS

1009583-20-3

Created by admin on Sat Dec 16 11:44:24 GMT 2023 , Edited by admin on Sat Dec 16 11:44:24 GMT 2023

PRIMARY

CAS

1009365-98-3

Created by admin on Sat Dec 16 11:44:24 GMT 2023 , Edited by admin on Sat Dec 16 11:44:24 GMT 2023

PRIMARY

PUBCHEM

59336911

Created by admin on Sat Dec 16 11:44:24 GMT 2023 , Edited by admin on Sat Dec 16 11:44:24 GMT 2023

PRIMARY

Related Record Type Details


					KN24QP9M3Q

11.BETA.-HYDROXYSTEROID DEHYDROGENASE TYPE 1

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					HLF8J24L87

ACTIVE MOIETY

Comments:

Compounds 7 and 8 (Scheme 1) are two 11-.BETA.-hsd1 inhibitors synthesized and investigated at Bristol-Myers Squibb.4 The synthesis of both 7 and 8 required the introduction of the adamantanol hydroxyl group with the desired stereochemistry.Many ketoreductases are commercially available, and this activity is very common in microbial strains. This paper describes screening to identify ketoreductases with the desired stereospecificity, initial preparation of the chiral alcohols with a commercial ketoreductase, and purification, cloning and expression of a more effective ketoreductase from Candida utilis ATCC 42181.